摘要:
Compounds having the formula (I), and enantiomers, and diastereomers, pharmaceutically-acceptable salts, thereof, are useful as kinase modulators, including Btk modulation, wherein R1, R2, R3, R4, Q, A and B are as defined herein.
摘要:
Compounds having the formula (I), and enantiomers, and diastereomers, pharmaceutically-acceptable salts, thereof, [PLEASE INSERT CHEMICAL STRUCTURE HERE] (I) are useful as kinase modulators, including Btk modulation, wherein R1, R2, R4, Q, Y, A and D are as defined herein.
摘要:
Compounds having the formula (I), and enantiomers, and diastereomers, pharmaceutically-acceptable salts, thereof, [PLEASE INSERT CHEMICAL STRUCTURE HERE] (I) are useful as kinase modulators, including Btk modulation, wherein R1, R2, R4, Q, Y, A and D are as defined herein.
摘要:
Compounds having the formula (I), and enantiomers, and diastereomers, pharmaceutically-acceptable salts, thereof, are useful as kinase modulators, including Btk modulation, wherein R1, R2, R3, R4, Q, A and B are as defined herein.
摘要:
The present invention provides pyrazole derived compounds of formula (I) useful for treating p38 kinase-associated conditions, where W, X, R1, R2, R3, R4, R5, R6 and m are as defined herein. The invention further pertains to pharmaceutical compositions containing at least one compound according to the invention useful for treating p38 kinase-associated conditions, and methods of inhibiting the activity of p38 kinase in a mammal.
摘要翻译:本发明提供了可用于治疗p38激酶相关病症的式(I)的吡唑衍生化合物,其中W,X,R 1,R 2,R 2, R 3,R 4,R 5,R 6和m如本文所定义。 本发明还涉及含有至少一种可用于治疗p38激酶相关病症的本发明化合物的药物组合物,以及抑制哺乳动物中p38激酶活性的方法。
摘要:
The present invention provides pyrazole derived compounds of formula (I) useful for treating p38 kinase-associated conditions, where G, X, R1, R2, R3, R4, R5, R6 and m are as defined herein. The invention further pertains to pharmaceutical compositions containing at least one compound according to the invention useful for treating p38 kinase-associated conditions, and methods of inhibiting the activity of p38 kinase in a mammal.
摘要:
Compounds having the formula (I), are effective as inhibitors of IMPDH enzyme and/or serine protease Factor VIIa, wherein B is a monocyclic or bicyclic carbocyclic or heterocyclic ring, D is a monocyclic or bicyclic carbocyclic or heterocyclic ring except when A is a heterocyclic ring, then D is a heterocyclic ring system, R is hydrogen or C1-4alkyl, and A, R1, R2 and R4 are as defined in the specification.
摘要:
The present invention discloses the identification of the novel inhibitors of IMPDH (inosine-5′-monophosphate dehydrogenase). The compounds and pharmaceutical compositions disclosed herein are useful in treating or preventing IMPDH-associated disorders, such as transplant rejection and autoimmune diseases.
摘要:
The present invention relates to compounds having the formula, and pharmaceutically-acceptable salts, prodrugs, solvates, isomers, and/or hydrates thereof, wherein Q is an optionally-substituted phenyl, pyridyl, pyridazinyl, pyrimidinyl, or pyrazinyl ring; R2 is alkyl or an amino group as defined herein; and Z is optionally-substituted oxadiazolyl or —C(═O)NR6, wherein R6 is lower alkyl or cyclopropyl. The compounds are surprisingly advantageous in preparing pharmaceutical compositions for treating p38 kinase related conditions and/or in methods of treating conditions associated with the activity of p38 kinase in a patient.
摘要翻译:本发明涉及具有下式的化合物及其药学上可接受的盐,前体药物,溶剂合物,异构体和/或其水合物,其中Q是任选取代的苯基,吡啶基,哒嗪基,嘧啶基或吡嗪基; R 2是如本文所定义的烷基或氨基; 和Z是任选取代的恶二唑基或-C(-O)NR 6,其中R 6是低级烷基或环丙基。 该化合物在制备用于治疗p38激酶相关病症的药物组合物和/或治疗与患者中p38激酶活性相关的病症的方法中令人惊奇地有利。
摘要:
The present invention relates to compounds having the formula, and pharmaceutically-acceptable salts, prodrugs, solvates, isomers, and/or hydrates thereof, wherein Q is an optionally-substituted pyridyl, ring; R2 is alkyl or an amino group as defined herein; and Z is optionally-substituted C(═O)NR6, wherein R6 is lower alkyl or cyclopropyl. The compounds are surprisingly advantageous in preparing pharmaceutical compositions for treating p38 kinase related conditions and/or in methods of treating conditions associated with the activity of p38 kinase in a patient.
摘要翻译:本发明涉及具有下式的化合物及其药学上可接受的盐,前体药物,溶剂合物,异构体和/或水合物,其中Q是任选取代的吡啶基环; R 2是如本文所定义的烷基或氨基; 和Z是任选取代的C(= O)NR 6,其中R 6是低级烷基或环丙基。 该化合物在制备用于治疗p38激酶相关病症的药物组合物和/或治疗与患者中p38激酶活性相关的病症的方法中令人惊奇地有利。